

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:  
He, et al.

CASE NO.: DM-6864-A

SERIAL NO.: 09/015,002

JUL 22 1999

GROUP ART UNIT: 1611

FILED: JANUARY 28, 1998

EXAMINER: Ford, J.

FOR: AZOLO TRIAZINES AND PYRIMIDINES

RECEIVED

JUL 28 1999

TECH CENTER 1600/29

Wilmington, Delaware  
July 20, 1999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56 (b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

The references cited in this Supplemental Information Disclosure Statement were submitted with the Information Disclosure Statement filed on February 18, 1999. However, because the year of publication of each of the cited references was not included in the original Information Disclosure Statement, the Examiner did not initial them as having been reviewed. In this Supplemental Information Disclosure Statement, Applicants are resubmitting those references including the year of publication for each reference. Applicants respectfully request review of the references provided in the Supplemental Information Disclosure Statement by the Examiner.

07/27/1999 AIBRAHIM 00000174 041928 09015002

01 FC:126 240.00 CH

DM-6864-A / USSN 09/015,002  
Supplemental IDS  
July 20, 1999

In accordance with \$1.97(c), this Supplemental Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311. Therefore, The fee of \$220.00 as set forth in \$1.7(p) should be charged to Deposit Account No. 04-1928.

Respectfully submitted,

*Maureen P. O'Brien* ✓

Maureen P. O'Brien, Ph.D., J.D.  
Attorney for Agent  
Registration No.: 42,043  
Telephone: 302-992-4528

DuPont Pharmaceuticals Company  
c/o. Legal-Patents  
1007 Market Street  
Wilmington, Delaware

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Assistant Commissioner for Patents, Washington, D.C. 20231 on

July 20, 1999

*Cathleen M. Collins*

Cathleen M. Collins